2. Search Result
Search Result
Results for "

FXIa

" in MedChemExpress (MCE) Product Catalog:

20

Inhibitors & Agonists

3

Peptides

1

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-151196
    FXIa-IN-10

    		Others Cardiovascular Disease
    FXIa-IN-10 (Compound 3f) is a potent activated factor XI (FXIa) inhibitor with an Ki of 0.17 nM. FXIa-IN-10 has good oral bioavailability .
    <em>FXIa</em>-IN-10
  • HY-150682
    FXIa-IN-9

    		Factor Xa Cardiovascular Disease
    FXIa-IN-9 (compound 3f) is a potent and selective FXIa inhibitor. FXIa-IN-9 can bind with FXIa and form hydrogen bond (human FXIa Ki: 0.17 nM, rabbit FXIa Ki: 0.5 nM). FXIa-IN-9 also has anticoagulant activity, and can be used in the research of thromboembolic diseases such as atrial fibrillation, stroke, myocardial infarction, deep vein thrombosis, and pulmonary embolism .
    <em>FXIa</em>-IN-9
  • HY-144658
    FXIa-IN-8

    		Factor Xa Cardiovascular Disease
    FXIa-IN-8 is a potent and selective FXIa inhibitor with an IC50 of 14.2 nM. FXIa-IN-8 shows antithrombotic activity without increasing the bleeding risk and obvious toxicitysup>[1].
    <em>FXIa</em>-IN-8
  • HY-157547
    FXIa-IN-14

    		Factor Xa Cardiovascular Disease
    FXIa-IN-14 (Compound 14c) is a FXIa inhibitor with an IC50 value of 15 nM .
    <em>FXIa</em>-IN-14
  • HY-145349
    FXIa-IN-6

    		Factor Xa Cardiovascular Disease
    FXIa-IN-6 is a potent FXIa inhibitor with selectivity against most of the relevant serine proteases (Ki = 0.3 nM).
    <em>FXIa</em>-IN-6
  • HY-128889
    FXIa-IN-1

    		Factor Xa Cardiovascular Disease
    FXIa-IN-1 (compound EP-7041) is a potent β-lactam covalent heparin-derived factor XIa (fXIa) inhibitor .
    <em>FXIa</em>-IN-1
  • HY-153817
    FXIa-IN-13

    		Factor Xa Cardiovascular Disease
    FXIa-IN-13 (example 1) is an Factor Xa inhibitor with antithrombotic activity. FXIa-IN-13 inhibits arteriovenous thrombosis in vivo and in vitro .
    <em>FXIa</em>-IN-13
  • HY-145354
    FXIa-IN-7

    		Factor Xa Cardiovascular Disease
    FXIa-IN-7 is a selective and orally bioavailable factor XIa inhibitor with an IC50 value of 0.4 nM.
    <em>FXIa</em>-IN-7
  • HY-163347
    FXIIa-IN-3

    		Others Cardiovascular Disease
    FXIIa-IN-3 (Compound 8) is a potent and selective Factor XIIa (FXIIa) inhibitor, with an IC50 of 0.045 μM. FXIIa-IN-3 also exhibits a substantial margin of selectivity against related serine proteases, including FXIa, FXa, and FIXa. FXIIa-IN-3 can be used for the research of thromboembolic diseases .
    FXIIa-IN-3
  • HY-145568
    Feniralstat

    KVD-824

    		 Ser/Thr Protease Cardiovascular Disease Metabolic Disease
    Feniralstat (compound 30), a pyrazole derivative, is a potent kallikrein inhibitor with an IC50 of 6.7 nM for Human plasma kallikrein (pKal). Feniralstat has no inhibition on Human KLKl, Human FXIa, Human Factor Xlla (all IC50>40 μM).
    Feniralstat
  • HY-137431
    Asundexian

    BAY-2433334

    		 Factor Xa Cardiovascular Disease
    Asundexian (BAY 2433334) is an orally active coagulation factor Xia (FXIa) inhibitor. Asundexian binds directly, potently, and reversibly to the active site of FXIa and thereby inhibits its activity. Asundexian inhibits human FXIa in buffer with an IC50 of 1 nM .
    Asundexian
  • HY-12631
    BMS-654457

    		Factor Xa Cardiovascular Disease
    BMS-654457 is a small-molecule, reversible inhibitor of factor XIa (FXIa), binding with human and rabbit FXIa with Kis of 0.2 and 0.42 nM, respectively.
    BMS-654457
  • HY-152150
    Thrombin inhibitor 7

    		Others Metabolic Disease
    Thrombin inhibitor 7 is a potent FXIIa inhibitor with IC50 values of 28 nM, >132 µM for FXIIa and FXIa, respectively. Thrombin inhibitor 7 shows low cytotoxicity .
    Thrombin inhibitor 7
  • HY-P6023
    D-Leu-Pro-Arg-Rh110-D-Pro

    		Factor Xa Cardiovascular Disease
    D-Leu-Pro-Arg-Rh110-D-Pro is a substrate for Factor Xa I (FXIa) with binding affinity. D-Leu-Pro-Arg-Rh110-D-Pro consists of Rhodamine 110 (HY-D0817) linked to a peptide chain through a cleavable bond. Cleavable bond cleavage enhances fluorophore intensity. D-Leu-Pro-Arg-Rh110-D-Pro can be used to detect FXIa activity .
    D-Leu-Pro-Arg-Rh110-D-Pro
  • HY-P6023B
    D-Leu-Pro-Arg-Rh110-D-Pro acetate

    		Factor Xa Cardiovascular Disease
    D-Leu-Pro-Arg-Rh110-D-Pro acetate is a substrate for Factor Xa I (FXIa) with binding affinity. D-Leu-Pro-Arg-Rh110-D-Pro acetate consists of Rhodamine 110 (HY-D0817) linked to a peptide chain through a cleavable bond. Cleavable bond cleavage enhances fluorophore intensity. D-Leu-Pro-Arg-Rh110-D-Pro acetate can be used to detect FXIa activity .
    D-Leu-Pro-Arg-Rh110-D-Pro acetate
  • HY-P6023A
    D-Leu-Pro-Arg-Rh110-D-Pro TFA

    		Factor Xa Cardiovascular Disease
    D-Leu-Pro-Arg-Rh110-D-Pro TFA is a substrate for Factor Xa I (FXIa) with binding affinity. D-Leu-Pro-Arg-Rh110-D-Pro TFA consists of Rhodamine 110 (HY-D0817) linked to a peptide chain through a cleavable bond. Cleavable bond cleavage enhances fluorophore intensity. D-Leu-Pro-Arg-Rh110-D-Pro TFA can be used to detect FXIa activity .
    D-Leu-Pro-Arg-Rh110-D-Pro TFA
  • HY-163348
    FXIIa-IN-4

    		Factor Xa Thrombin Cardiovascular Disease
    FXIIa-IN-4 (compound 22) is a potent, selective human FXIIa inhibitor with the IC50 of 0.032 μM, 0.30 μM, ＞50 μM for FXIIa, thrombin and FXIa, respectively. FXIIa-IN-4 can be used for study of anticoagulant .
    FXIIa-IN-4
  • HY-P99794
    Osocimab

    BAY 1213790

    		 Factor Xa Cardiovascular Disease
    Osocimab (BAY 1213790), an anti-FXIa antibody (Ki=2.4 nM; EC50=0.2 nM). FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects .
    Osocimab
  • HY-117290
    BMS-962212

    		Factor Xa Cardiovascular Disease
    BMS-962212 is a direct, reversible, selective factor XIa (FXIa) inhibitor . BMS-962212 is well tolerated, with fast onset of pharmacodynamic (PD) responses and rapid elimination. BMS-962212 increases exposure dependently in activated partial thromboplastin time, and decreases exposure dependently in FXI clotting activity .
    BMS-962212
  • HY-128570
    FD-IN-1

    		Complement System Inflammation/Immunology
    FD-IN-1 (Compound 12) is an orally bioavailable and selective factor D (FD) inhibitor with an IC50 of 12 nM. Complement FD, a highly specific S1 serine protease, plays a central role in the alternative complement pathway of the innate immune system. FD-IN-1 also inhibits factor XIa (FXIa) and Tryptase β2 with IC50s of 7.7 and 6.5 µM, respectively .
    FD-IN-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: